SPIB is a novel prognostic factor in diffuse large B‐cell lymphoma that mediates apoptosis via the PI3K‐AKT pathway

Although the clinical outcomes of diffuse large B‐cell lymphoma (DLBCL) have improved in the immunochemotherapy era, approximately one‐third of patients develop intractable disease. To improve clinical outcomes for these patients, it is important to identify those with poor prognosis prior to initia...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Sci
Hlavní autoři: Takagi, Yusuke, Shimada, Kazuyuki, Shimada, Satoko, Sakamoto, Akihiko, Naoe, Tomoki, Nakamura, Shigeo, Hayakawa, Fumihiko, Tomita, Akihiro, Kiyoi, Hitoshi
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2016
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5021043/
https://ncbi.nlm.nih.gov/pubmed/27348272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13001
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky